Kirkland Represents Teva In $5B Ratiopharm Deal

Law360, New York (March 18, 2010, 1:28 PM EDT) -- In a move designed to help drive its growth in key European markets, Teva Pharmaceutical Industries Ltd. has agreed to fork over $4.93 billion to acquire Ratiopharm GmbH, Germany's second-largest generics maker and the sixth-largest generic-drug company worldwide.

The acquisition, announced Thursday, will boost Teva's European business from sales of $3.3 billion in 2009 to joint pro forma sales of $5.2 billion, the company said.

Following the transaction, Teva will improve its market position in Germany ā€” the world's second-largest generic-drug market, valued at approximately $8.8...
To view the full article, register now.